ViroBlogy

Via Scoop.it – Virology News

“2011 was an important year for Medicago as we reported positive clinical results from both our Phase II pandemic H5N1 influenza vaccine clinical trial and Phase I seasonal influenza trial, commenced operations at our 97,000-square-foot facility in North Carolina, and raised over $65 million of equity with investments from Mitsubishi Tanabe Pharma Corporation and other healthcare-focused funds,” said Andy Sheldon, President and Chief Executive Officer of Medicago. “We have already made significant progress in 2012, establishing a strategic alliance with Mitsubishi Tanabe, completing the fourth milestone related to the DARPA project, and moving ahead with our internal rabies vaccine candidate. We expect to continue to take valuable steps forward including the initiation a Phase I clinical trial for a one-dose H5N1 VLP vaccine, the completion of the remaining two DARPA milestones, initiating a US Phase IIa clinical trial for a quadrivalent seasonal flu vaccine, as well as continuing our efforts to execute additional contracts for our VLP technology.”

Going green: you know the rest!  B-)

Via www.marketwatch.com

This entry was posted on 30 March, 2012 at 08:51 and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.